Cardiac contractility modulation in left ventricular systolic dysfunction: one-year experience in a pilot study and design of a prospective registry

Enhancing myocardial function with cardiac contractility modulation: potential and challenges

“…The Optimizer system, a CCM device, is now commercially available and approved for use in much of Europe, 43 and ongoing clinical trials in the United States are investigating its effects on HF mortality and morbidity 43 . Recently, there was a prospective registry that was designed to identify the subsets of patients who benefited more from CCM and to analyse how CCM affects those clinical outcomes in the long term 41 . An overview of the effects of CCM on HFrEF patients can be found in Table 1 .…”

“…Some studies have observed improvements in quality of life and functional status 47 but no significant differences in 6‐minute walk distance, arrhythmic events, hospitalizations, or mortality 48 . Further large‐scale randomized controlled trials are needed to confirm the long‐term benefits of CCM therapy 33,40,41 . Although tricuspid regurgitation (TR) is a potential complication of CCM device implantation, recent evaluations suggest that it does not worsen after the implantation of right ventricular electrodes for CCM therapy 49 …”

“… 43 Recently, there was a prospective registry that was designed to identify the subsets of patients who benefited more from CCM and to analyse how CCM affects those clinical outcomes in the long term. 41 An overview of the effects of CCM on HFrEF patients can be found in Table 1 .…”

“… 48 Further large‐scale randomized controlled trials are needed to confirm the long‐term benefits of CCM therapy. 33 , 40 , 41 Although tricuspid regurgitation (TR) is a potential complication of CCM device implantation, recent evaluations suggest that it does not worsen after the implantation of right ventricular electrodes for CCM therapy. 49 …”